A
Alicia J. Allred
Researcher at Janssen Pharmaceutica
Publications - 14
Citations - 812
Alicia J. Allred is an academic researcher from Janssen Pharmaceutica. The author has contributed to research in topics: Multiple myeloma & B-Cell Maturation Antigen. The author has an hindex of 6, co-authored 14 publications receiving 249 citations.
Papers
More filters
Journal ArticleDOI
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G. Berdeja,Deepu Madduri,Saad Z. Usmani,Andrzej Jakubowiak,Mounzer Agha,Adam D. Cohen,A. Keith Stewart,Parameswaran Hari,Myo Htut,Alexander M. Lesokhin,Abhinav Deol,Nikhil C. Munshi,Elizabeth O'Donnell,David Avigan,Indrajeet Singh,Enrique Zudaire,Tzu-Min Yeh,Alicia J. Allred,Yunsi Olyslager,Arnob Banerjee,Carolyn C. Jackson,Jenna D. Goldberg,Jordan M. Schecter,William Deraedt,Sen Hong Zhuang,Jeffrey R. Infante,Dong Geng,Xiaoling Wu,Marlene J Carrasco-Alfonso,Muhammad Akram,Farah Hossain,Syed Rizvi,Frank Fan,Yi Lin,Thomas Martin,Sundar Jagannath +35 more
TL;DR: The CARITUDE-1 trial as discussed by the authors evaluated the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies.
Journal ArticleDOI
Results from CARTITUDE-1: A Phase 1b/2 Study of JNJ-4528, a CAR-T Cell Therapy Directed Against B-Cell Maturation Antigen (BCMA), in Patients with Relapsed and/or Refractory Multiple Myeloma (R/R MM)
Deepu Madduri,Saad Z. Usmani,Sundar Jagannath,Indrajeet Singh,Enrique Zudaire,Tzu-Min Yeh,Alicia J. Allred,Arnob Banerjee,Jenna D. Goldberg,Jordan M. Schecter,Sen Zhuang,Jeffrey R. Infante,Syed Rizvi,Xiaohu (Frank) Fan,Andrzej Jakubowiak,Jesus G. Berdeja +15 more
TL;DR: JNJ-68284528 (JNJ4528) is a CAR-T therapy containing two BCMA-targeting single-domain antibodies designed to confer avidity as mentioned in this paper.
Journal ArticleDOI
Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.
Jesus G. Berdeja,Deepu Madduri,Saad Z. Usmani,Indrajeet Singh,Enrique Zudaire,Tzu-Min Yeh,Alicia J. Allred,Yunsi Olyslager,Arnob Banerjee,Jenna D. Goldberg,Jordan M. Schecter,Dong Geng,Xiaoling Wu,Marlene Carrasco-Alfonso,Syed Rizvi,Frank Fan,Andrzej Jakubowiak,Sundar Jagannath +17 more
TL;DR: CARTITUDE-1 (NCT03548207) is a chimeric antigen receptor T (CAR-T) cell therapy containing 2 BCMA-targeting single-domain antibodies that presents a newwindow of opportunity for CAR-T cell therapy in patients with central giant cell granuloma.
Journal ArticleDOI
CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma
Deepu Madduri,Jesus G. Berdeja,Saad Z. Usmani,Andrzej Jakubowiak,Mounzer Agha,Adam D. Cohen,A. Keith Stewart,Parameswaran Hari,Myo Htut,Elizabeth O'Donnell,Nikhil C. Munshi,David Avigan,Abhinav Deol,Alexander M. Lesokhin,Indrajeet Singh,Enrique Zudaire,Tzu-Min Yeh,Alicia J. Allred,Yunsi Olyslager,Arnob Banerjee,Jenna D. Goldberg,Jordan M. Schecter,Carolyn C. Jackson,William Deraedt,Sen Hong Zhuang,Jeffrey R. Infante,Dong Geng,Xiaoling Wu,Marlene J. Carrasco,Muhammad Akram,Farah Hossain,Syed Rizvi,Frank Fan,Sundar Jagannath,Yi Lin,Thomas Martin +35 more
TL;DR: Cilta-cel is a chimeric antigen receptor T (CAR-T) cell therapy with 2 B-cell maturation antigen-targeting single-domain antibodies designed to confer avidity in patients with relapsed/refractory multiple myeloma in the US.
Journal ArticleDOI
Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.
Saad Z. Usmani,Jesus G. Berdeja,Deepu Madduri,Andrzej Jakubowiak,Mounzer Agha,Adam D. Cohen,Parameswaran Hari,Tzu-Min Yeh,Yunsi Olyslager,Arnob Banerjee,Carolyn C. Jackson,Alicia J. Allred,Enrique Zudaire,William Deraedt,Xiaoling Wu,Marlene Carrasco-Alfonso,Muhammad Akram,Yi Lin,Thomas G. Martin,Sundar Jagannath +19 more
TL;DR: A single infusion of cilta-cel yielded early, deep, and durable responses in heavily pretreated pts with MM, with a manageable safety profile at the RP2D.